Multiple vergrößerte stoffwechselaktive Lymphknoten im ¹⁸F-FDG PET/CT nach Anti-CTLA-4-Antikörpertherapie beim metastasierten Melanom – Krankheitsprogress oder immunbedingte Nebenwirkung?

• Literatur

• 1 Kaehler KC, Piel S, Livingstone E et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37: 485-498
• 2 Bronstein Y, Ng CS, Hwu P et al. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. Am J Roentgenol Am J Roentgenol 2011; 197: W992-W1000
• 3 Vogel WV, Guislain A, Kvistborg P et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012; 30: e7-e10
• 4 Koo PJ, Klingensmith WC, Lewis KD et al. Anti-CTLA4 antibody therapy related complications on FDG PET/CT. Clin Nucl Med 2014; 39: e93-e96
• 5 Spiro J, Maintz D, Persigehl T. Responsekriterien bei malignem Melanom. Radiologe 2015; 55: 127-135
• 6 Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420